MCL1 has critical antiapoptotic functions and its levels are tightly regulated by ubiquitylation 19 and degradation, but mechanisms that drive this degradation, particularly in solid tumors, remain 20 to be established. We show here in prostate cancer cells that increased NOXA, mediated by 21 activation of an integrated stress response, drives the degradation of MCL1, and identify the 22 mitochondria-associated ubiquitin ligase MARCH5 as the primary mediator of this NOXA-23 dependent MCL1 degradation. Therapies that enhance MARCH5-mediated MCL1 degradation 24 markedly enhance apoptosis in response to a BH3 mimetic agent targeting BCLXL, which may 25 provide for a broadly effective therapy in solid tumors. Conversely, increased MCL1 in response 26 to MARCH5 loss does not sensitize to BH3 mimetic drugs targeting MCL1, but instead also 27 sensitizes to BCLXL inhibition, revealing a codependence between MARCH5 and MCL1 that 28 may also be exploited in tumors with MARCH5 genomic loss. 29 30 33 prostate cancer, CRPC). The majority will initially respond to agents that further suppress AR, 34 but most men relapse within 1-2 years and these relapses appear to be driven by multiple AR 35 dependent and independent mechanisms (1,2), which may include increased expression of anti-36 apoptotic proteins. The anti-apoptotic BCL2 family proteins (including BCL2, BCLXL, and 37 MCL1) act by neutralizing BAX and BAK, and by inhibiting the BH3-only pro-apoptotic 38 proteins that can activate BAX/BAK (primarily BIM) (3). These interactions are mediated by the 39 BH3 domain, and BH3-mimetic drugs can enhance apoptosis by mimicking the activity of BH3-40 only pro-apoptotic proteins and thereby antagonizing the anti-apoptotic BCL2 family proteins 41 (4,5). ABT-737 (6) and ABT-263 (navitoclax, orally bioavailable analogue of ABT-737) (7) are 42 BH3-mimetics that directly bind to BCL2, BCLXL, and BCLW (but not MCL1), which blocks 43 3 their binding to pro-apoptotic BH3 only proteins such as BIM and their ability to neutralize 44 BAX/BAK. Navitoclax has single-agent activity in hematological malignancies (8), but causes 45 thrombocytopenia due to BCLXL inhibition. A BCL2-specific agent that spares platelets (ABT-46 199, venetoclax) is similarly active and is now FDA approved for chronic lymphocytic leukemia 47 (9,10). 48 In contrast, most solid tumors are resistant to these agents (11), which appears to reflect an 49 important role for MCL1 (11)(12)(13) (14) (15)(16). Indeed, preclinical studies indicate that navitoclax may be 50 efficacious in solid tumors when used in combination with other agents acting through a variety 51 of mechanisms, including by decreasing MCL1 expression (11,(16)(17)(18)(19)(20)(21)(22). BH3 mimetics that target 52 MCL1 (including AMG176, S63845 and AZD5991) are now becoming available and may have 53 single agent activity in a subset of tumors (23-28), but efficacy in most solid tumors will likely 54 still require combination therapies (4,23,26). Moreover, the toxicities associated with direct 55 MCL1 antagonists, alone or in combination therapies, remain to be determined. 56 We reported previously that navitoclax (acting through BCLXL blockade), in combination 57 with several kinase inhibitors (erlotinib, lapatinib, cabozantinib, sorafenib) could induce rapid 58 and marked apoptotic responses in PCa cells (22). This response was preceded by a dramatic 59 increase in MCL1 degradation, and we confirmed that navitoclax could drive apoptotic responses 60 in vitro and in vivo in PCa cell that were depleted of MCL1 by RNAi or CRISPR. Significantly, 61 the enhanced MCL1 degradation in response to kinase inhibitors was not mediated by well-62 established mechanisms including through GSK3β-mediated phosphorylation (and the 63 downstream ubiquitin ligases βTrCP or Fbw7), or by the ubiquitin ligase HUWE1/MULE that 64 has been reported to mediate both basal MCL1 degradation and MCL1 degradation in response 65 to DNA damage and NOXA binding (29)(30)(31)(32). 66 In this study we found that treatment with kinase inhibitors initiates an integrated stress 67 response (ISR) leading to increased ATF4 protein and subsequent increased transcription of 68 NOXA, and that the enhanced degradation of MCL1 was NOXA-dependent. We further 69 identified the mitochondria-associated ubiquitin ligase MARCH5 as the mediator of this stress-70 induced and NOXA-dependent MCL1 degradation. MARCH5 is a RING-finger E3 ligase with 71 an established function in mediating the ubiquitylation and degradation of several proteins that 72 regulate mitochondrial fission and fusion (33-37). MARCH5 depletion both abrogated the 73 decrease in MCL1 in response to cellular stress and substantially increased basal MCL1 in 74 4 multiple epithelial cancer cell lines, indicating that MARCH5 makes a major contribution to 75 regulating MCL1 levels under basal conditions and in responses to cellular stress. Significantly, 76 while the MARCH5 mediated degradation of MCL1 markedly sensitized tumor cells to BCLXL 77 inhibition, MARCH5 depletion, which occurs in ~5% of PCa, also sensitized to BCLXL 78 inhibition despite increased MCL1, revealing a codependency between MCL1 and MARCH5. 79 Together these results reveal therapeutic opportunities for the use of agents targeting BCLXL in 80 solid tumors. 81 82 Results 83 84 85 As we reported previously, multiple kinase inhibitors including the EGFR inhibitor erlotinib 86 could rapidly (within 4 hours) and markedly enhance the proteasome-dependent degradation of 87 MCL1 (Figure S1A,B) . Moreover, we found that this occurred by a mechanism that was 88 independent of the ubiquitin ligase HUWE1 (MULE) and of ubiquitin ligases downstream of 89 GSK3β (βTRCP, FBW7) (22). BIM and NOXA are the primary BH3-only proteins that bind 90 MCL1, and can increase or decrease its stability, respectively (32,38,39). Consistent with our 91 previous results, 4 hour treatment with erlotinib did not decrease BIM, indicating that loss of 92 BIM is not a basis for the marked decrease in MCL1 protein ( Figure 1A) . In contrast, NOXA 93 expression was increased by erlotinib, suggesting this may drive the increased MCL1 94 degradation. Indeed, depleting NOXA with 3 different siRNA suppressed this decrease in MCL1 95 ( Figure 1B) . Moreover, more complete depletion of NOXA with the pooled siRNAs prevented 96 the erlotinib-mediated MCL1 reduction, indicating a NOXA-dependent mechanism for 97 decreasing MCL1 ( Figure 1C) . In contrast, while depletion of BIM by siRNA caused a decrease 98 in basal MCL1, it did not prevent the further decrease in MCL1 in response to erlotinib ( Figure   99 1D). 100 Erlotinib rapidly (within 2 hours) upregulated NOXA mRNA ( Figure 1E) , indicating a 101 transcriptional mechanism for increasing NOXA protein. Consistent with this finding, inhibiting 102 new synthesis of mRNA with actinomycin D decreased basal NOXA protein, and prevented the 103 erlotinib-mediated upregulation of NOXA ( Figure 1F ). Actinomycin D similarly decreased basal 104 5 MCL1 protein expression through transcriptional repression, but importantly prevented the 105 erlotinib-mediated MCL1 reduction ( Figure 1F ).
Introduction

31
Androgen deprivation therapy to suppress activity of the androgen receptor (AR) is the standard 32 treatment for metastatic prostate cancer (PCa), but tumors invariably recur (castration-resistant 6 eIF2α phosphorylation (44), decreased basal ATF4 and suppressed the erlotinib-mediated 136 increase in ATF4 and NOXA, providing further evidence for this pathway ( Figure 2C ). 137 Consistent with these findings, ISRIB suppressed the erlotinib-mediated increase in NOXA 138 mRNA ( Figure 2D ), while MCL1 mRNA was unaffected by these treatments (Figure 2E ). 139 Together, these findings indicate that activation of the ISR by erlotinib drives the rapid induction 140 of NOXA, which then promotes MCL1 degradation. 141 142 MARCH5 mediates kinase inhibitor/NOXA-dependent MCL1 degradation 143 We next sought to identify E3 ligases that contribute to kinase inhibitor-mediated and NOXA-144 dependent MCL1 degradation. MCL1 is a substrate for the ubiquitin ligase HUWE1 (MULE), 145 and HUWE1 has been reported to mediate MCL1 degradation by NOXA (29) (30) (31) . However, we 146 reported previously that while HUWE1 depletion could increase basal MCL1 levels, it did not 147 prevent the increased degradation of MCL1 in response to kinase inhibitors (22) . Figure 3A   148 shows that HUWE1 depletion does not affect the erlotinib-mediated increase in NOXA, and that 149 it does not prevent the subsequent decrease in MCL1. 150 NEDD8 conjugation is essential for cullin-dependent E3 ligases to ubiquitylate their 151 substrates. To determine the role of cullin-dependent E3 ligases in MCL1 degradation in 152 response to tyrosine kinase inhibition, we examined whether NEDD8 inhibition could prevent 153 the effect of tyrosine kinase inhibitors. Treatment with NEDD8 inhibitor MLN4924 increased 154 p27 (a known target of cullin-dependent E3 ligase CUL4), but did not increase MCL1 or block 155 the effects of erlotinib ( Figure 3B ). Indeed, MLN4924 moderately decreased MCL1 protein, 156 which may be due to an increase in NOXA, whose degradation is mediated by a cullin-dependent 157 E3 ligase (45). MLN4924 similarly failed to prevent the decrease in MCL1 in response to 158 lapatinib (EGFR/ERBB2 inhibitor) ( Figure 3C ), indicating that a cullin-independent mechanism 159 is driving the increased MCL1 degradation. 160 We then hypothesized that a cullin-independent E3 ligase that localizes to mitochondria, 161 where MCL1 is mainly located, may promote MCL1 degradation in response to tyrosine kinase 162 inhibition. To assess this hypothesis, we first examined the well-known mitochondria-associated 163 cullin-independent E3 ligase PARKIN, which has been implicated as a ubiquitin ligase for 164 MCL1 (46) . However, while PARKIN depletion increased its target protein p62, it did not 165 increase MCL1 or block the effect of erlotinib ( Figure 3D ). MARCH5 is another mitochondria-7 associated cullin-independent E3 ligase that has been implicated as a regulator of MCL1 (37, 47) . 167 Significantly, depleting MARCH5 with siRNA increased basal expression of MCL1 and a 168 known MARCH5 substrate, MiD49, in LNCaP cells ( Figure 3E and Figure S2A ). MARCH5 169 depletion did not increase MCL1 mRNA ( Figure S2B ), further supporting a posttranscriptional 170 mechanism for increasing MCL1. MARCH5 depletion also increased basal MCL1 in PC3 PCa 171 cells ( Figure 3F ) and in additional prostate, breast and lung cancer cell lines ( Figure S2C-H) . 172 These results show that MARCH5 is a major mediator of basal MCL1 degradation in epithelial 173 cancer cell lines. 174 Significantly, MARCH5 depletion prevented the decrease in MCL1 by erlotinib and 175 cabozantinib (C-MET/VEGFR2 inhibitor) in LNCaP and PC3 cells ( Figure 3E -G), indicating 176 that the decreases in MCL1 by these kinase inhibitors are mediated by MARCH5. In contrast, 177 MARCH5 depletion did not prevent MCL1 loss in cells treated with dinaciclib ( Figure 3E ), 178 which decreases MCL1 mRNA through inhibition of CDK9 and subsequent decrease in MCL1 179 transcription. To confirm these findings, we then used CRISPR/CAS9 to delete MARCH5. 180 Consistent with the RNAi results, there was a marked increase of MCL1 expression, as well of 181 the MARCH5 substrate MiD49, in each of three MARCH5 depleted lines ( Figure 3H ). 182 Moreover, erlotinib no longer decreased MCL1 in these MARCH5 depleted lines ( Figure 3H ). 183 As expected, transient overexpression of exogenous MARCH5 decreased MCL1 in control and 184 MARCH5 depleted cells ( Figure 3I ). 185 Interestingly, and consistent with a previous report (47), MARCH5 depletion by CRISPR or 186 siRNA also increased NOXA protein ( Figure 3H and Figure S3A , respectively). MARCH5 187 depletion did not increase, but instead decreased NOXA mRNA ( Figure S3B ), indicating this 188 increase in NOXA protein is through a post-transcriptional mechanism. One plausible 189 mechanism is through increased binding to MCL1, as a previous study found that MCL1 could 190 protect NOXA from proteasome-mediated degradation (48). Consistent with this mechanism, the 191 increased levels of NOXA and of BIM in MARCH5 depleted cells coincided with increased 192 binding of these proteins to MCL1 ( Figure 3J ). To further assess this mechanism, we treated 193 cells with an MCL1-targeted BH3 mimetic agent, S63845, to interfere with BH3 domain 194 mediated interactions with MCL1. Significantly, S63845 decreased both NOXA and BIM in the 195 MARCH5 depleted cells, consistent with them being stabilized by MCL1 ( Figure 3K ). Of note, 196 S63845 increased MCL1 in both the control and MARCH5 depleted cells, indicating that 197 8 additional ubiquitin ligases may partially compensate for MARCH5 loss in driving basal MCL1 198 degradation. 199 We also examined the effects on NOXA and BIM of depleting or overexpressing MCL1. 200 Cells with CRISPR-mediated MCL1 depletion had markedly reduced NOXA and BIM, 201 providing further evidence that MCL1 protects both from degradation ( Figure 3L ). Conversely, 202 NOXA and BIM were increased in cells that overexpress ectopic MCL1 ( Figure 3M ). However, 203 while MCL1 levels were comparable in cells overexpressing ectopic MCL1 and in MARCH5 204 depleted cells, the increases in NOXA and BIM were greater in the latter MARCH5 depleted 205 cells. One explanation for this difference with respect to NOXA (and possibly BIM) is that the 206 MARCH5-mediated degradation of MCL1 in MCL1-NOXA complexes may be coupled to the 207 degradation of NOXA by a distinct ubiquitin ligase. 208 209 EGFR inhibition does not alter MARCH5 expression or activity 210 The above findings indicated that increased NOXA in response to erlotinib was driving the 211 MARCH5-mediated ubiquitylation and degradation of MCL1. Consistent with this conclusion, 212 we found by coimmunoprecipitation that erlotinib treatment, in combination with proteasome 213 inhibition, enhanced the interaction between MARCH5 and MCL1 ( Figure 4A ). Importantly, 214 phosphorylation of BIM and NOXA can modulate their interaction with MCL1, suggesting that 215 kinase inhibitors may further be enhancing MCL1 ubiquitylation and degradation through effects 216 on phosphorylation of BIM, NOXA, or MCL1 that modulate NOXA/BIM-MCL1 interactions 217 (49-51). We have previously found that erlotinib did not alter MCL1 phosphorylation at sites that 218 have been shown to enhance its ubiquitylation and degradation (22). To further assess the role of 219 phosphorylation in erlotinib-mediated MCL1 degradation, we used phospho-tag gels and 220 examined the phosphorylation state of these proteins. Erlotinib treatment did not have any clear 221 effects on the phosphorylation of MCL1, BIM, or NOXA in cells cultured in complete medium 222 (FBS) or cultured in medium with charcoal stripped serum (CSS) to deplete steroids ( Figure 4B ). 223 Similarly, erlotinib did not alter phosphorylation in MARCH5 depleted cells. As a positive 224 control, EGF stimulation dramatically increased BIM phosphorylation. 225 In parallel with the above experiments, we asked directly whether erlotinib enhances 226 MCL1 interaction with NOXA versus BIM. This was assessed in MARCH5 knockout cells to 227 avoid effects due to increased MCL1 interaction with MARCH5 by erlotinib. Erlotinib treatment 9 did not clearly enhance MCL1 binding of NOXA versus BIM ( Figure 4C ). As expected, 229 treatment with S63845 decreased both NOXA and BIM binding to MCL1. 230 We next asked whether there were alterations in MARCH5 expression or activity that may be 231 enhancing its ubiquitylation of MCL1. We first examined effects of erlotinib versus MARCH5 232 depletion on MARCH5 substrates. Treatment with erlotinib again increased NOXA and 233 decreased MCL1, but did not decrease other MARCH5 substrates (MiD49, MFN1, and 234 FUNDC1) ( Figure 4D ). Interestingly, while MiD49 was increased in the MARCH5 knockout 235 cells (see also Figure 3E and 3H), MFN1 and FUNDC1 were not altered, indicating that these 236 latter substrates are not undergoing MARCH5-mediated degradation under basal conditions. In 237 any case, this result indicates that erlotinib is not generally enhancing MARCH5 activity. 238 We then asked whether erlotinib alters the mitochondrial localization of MARCH5, or of 239 MCL1. Consistent with previous reports, cellular fractionation showed that MARCH5 was 240 primarily located to mitochondria ( Figure 4E ). Treatment with erlotinib for 2 hours (prior to a 241 substantial decrease in MCL1) did not change this localization of MARCH5. Moreover, it did 242 not increase the mitochondrial localization of MCL1, BIM or NOXA, indicating that erlotinib-243 mediated MCL1 degradation is not through increased targeting of these latter proteins to 244 mitochondria. Finally, MARCH5 depletion did not clearly alter the fraction of MCL1 associated 245 with mitochondria. 246 As MARCH5 may be activated by mitochondrial stress, we also asked whether tyrosine 247 kinase inhibition had acute effects on mitochondria that may alter MARCH5 function. To 248 address this we examined mitochondrial respiration in response to erlotinib or lapatinib in 249 LNCaP-derived C4-2 cells, which were more suitable for these studies as they had stronger 250 attachment to the culture plate. Similarly to LNCaP cells, treatment with erlotinib or lapatinib for 251 4 hours under conditions used for the Seahorse assays decreased MCL1 in C4-2 cells (Figure 252 4F). We then treated with erlotinib or lapatinib for 2 hours and assessed oxygen consumption. 253 Neither erlotinib nor lapatinib changed maximal oxygen consumption rate ( Figure 4G , H), 254 suggesting that EGFR inhibition is not promoting functional damage to mitochondrial regarding 255 ATP production. Intriguingly, erlotinib and lapatinib increased basal oxygen consumption (ATP 256 linked respiration) ( Fig. 4G, I) , indicating a shift from fermentation to increased oxidative 257 phosphorylation. The precise basis for this metabolic adaptation, and whether it is linked to 258 activation of a stress response, is not clear. In any case, these findings indicate that MARCH5 is 10 not altered in response to erlotinib, and that its increased degradation of MCL1 is driven 260 primarily by the increase in NOXA.
262
Mitochondria-targeted agents can increase MCL1 degradation by MARCH5-dependent 263 mechanism 264 MARCH5 regulates mitochondrial fission and fusion in response to mitochondrial stress (33-37), 265 suggesting that agents that alter mitochondria functions may enhance MARCH5-mediated 266 degradation of MCL1 by a distinct mechanism. To assess this hypothesis, we examined the 267 effects of a series of mitochondria-targeted agents on MCL1. Actinonin is an inhibitor of the 268 human mitochondrial peptide deformylase that blocks mitochondrial protein translation (52).
269
Four-hour treatment with actinonin decreased MCL1 in LNCaP cells ( Figure 5A ). However, it 270 also increased NOXA, suggesting that it may be acting similarly to tyrosine kinase inhibitors 271 through an ISR, rather than by directly through MARCH5. Gamitrinib-TPP is a mitochondrial 272 HSP90 inhibitor and can induce MCL1 degradation in glioblastoma cells (53). Consistent with 273 previous data (54,55), gamitrinib-TPP rapidly decreased MCL1 in LNCaP cells, and this was 274 also associated with an increase in NOXA ( Figure 5B ). The pyruvate dehydrogenase/α-275 ketoglutarate dehydrogenase inhibitor CPI-613 is another clinically promising agent that targets 276 mitochondria (56). Similar to actinonin and gamitrinib-TPP, treatment with CPI-613 decreased 277 MCL1 and also increased NOXA ( Figure 5C ). 278 Significantly, each of these mitochondria-targeted agents increased ATF4 ( Figure 5C ), 279 indicating an ISR mechanism for increasing NOXA. Consistent with this finding, and with a 280 previous report on gamitrinib-TPP (54), treatment with ISRIB impaired the upregulation of 281 ATF4 and NOXA, and the reduction of MCL1, by each of these mitochondria-targeted agents 282 ( Figure 5C ). Moreover, depleting NOXA with siRNA prevented the decrease in MCL1 in 283 response to each of these agents ( Figure 5D ). Together these findings indicated that the increased 284 MCL1 degradation in response to these agents was being driven by increased NOXA 285 downstream of an ISR. 286 As further evidence for this conclusion, we found that the decrease in MCL1 by these 287 mitochondria-targeted agents was proteasome-dependent, and was not associated with an 288 increase in p53 ( Figure 5E , F). Finally, we used a caspase inhibitor to confirm that these 289 mitochondrial-targeted agents were not increasing MCL1 degradation through release and 290 11 activation of caspases, which can degrade MCL1 ( Figure 5F , Figure S4A ). As a positive control 291 for caspase inhibition, we showed that Z-DEVD-FMK could prevent caspase cleavage in 292 response to erlotinib in combination with ABT-737 ( Figure 5F , Figure S4A ). 293 We next used siRNA to determine whether MCL1 degradation in response to these 294 mitochondrial-targeted agents was mediated by MARCH5. Depleting MARCH5 markedly 295 increased MCL1 and prevented the MCL1 loss in response to erlotinib and actinonin, although 296 the effects of gamitrinib-TPP and CPI-613 were only partially suppressed, suggesting other 297 ubiquitin ligases may contribute to this MCL1 degradation and partially compensate for the loss 298 of MARCH5 ( Figure 5G ). Indeed, depletion of HUWE1 (which more modestly increased 299 MCL1) partially impaired the effects of CPI-613 ( Figure 5H ). Finally, as expected and consistent Figure S5A ). In contrast, 313 HUWE1 loss was very rare ( Figure 6C ). Interestingly, assessing genomic alterations across 314 cancers, MARCH5 loss appears to be most common in PCa ( Figure 6D ). Significantly, this may 315 reflect its genomic location adjacent to PTEN at 10q23, and hence co-deletion with PTEN. 316 Indeed, in the TCGA primary PCa dataset, all cases with deep deletion of MARCH5 also have 317 PTEN deletion ( Figure 6E ). In contrast, MARCH5 deletion appears to be occurring independently 318 of PTEN loss in a subset of metastatic PCa.
319
MCL1 amplification and MARCH5 loss generally occur in distinct tumors, although their 320 mutual exclusivity is not statistically significant ( Figure 6F and Figure S5B , C). Relative to 12 MARCH5 and MCL1, oncogenic alterations in the genes encoding NOXA (PMAIP1) and BIM 322 (BCL2L11) are rare ( Figure 6F and Figure S5B , C). Finally, shallow deletions of MARCH5, 323 suggesting single copy losses, appear to be relatively common in PCa, with a higher frequency in 324 metastatic castration-resistant PCa versus primary PCa ( Figure 6G , H, and Figure S5D , E). 325 Together these results support a tumor suppressor function for MARCH5, which may be related 326 to its negative regulation of MCL1. 327 328 MARCH5 loss decreases dependence on MCL1 329 The increased MCL1 in MARCH5 depleted cells suggested that these cells may have an 330 increased dependence on MCL1. To assess effects of MARCH5 loss on responses to MCL1 331 antagonists, we treated parental versus MARCH5 knockout cells with S63845. As expected, both 332 NOXA and BIM were markedly increased in the MARCH5 knockout cells ( Figure 7A ). S63845 333 at the lowest concentration examined (1 µM) both stabilized MCL1 and decreased NOXA and 334 BIM, consistent with S63845 binding to MCL1 and displacing NOXA and BIM, and with their 335 subsequent increased degradation. Surprisingly, despite the apparent substantial displacement of 336 NOXA and BIM from MCL1, the increase in apoptosis (as assessed by cleaved caspase 3, CC3, 337 and cleaved PARP, cPARP) was only observed at the highest concentration of drug (20 µM).
338
Identical results were obtained with a second MCL1 antagonist (AZD5991) ( Figure 7B ). We also 339 examined cells stably overexpressing ectopic MCL1. These cells similarly had marked increases 340 in NOXA and BIM, which were decreased in response to 1 µM S63845 ( Figure 7C ) or AZD5991 341 ( Figure 7D ), but apoptotic responses again required high drug concentrations. 342 Although the MARCH5 depleted and MCL1 overexpressing cells showed increased 343 apoptosis in response to MCL1 antagonists, it was unclear why (if it was an on-target effect) it 344 should require substantially higher drug concentrations than those needed for release of BIM and 345 NOXA. One contributing factor may be that the BIM and NOXA that is displaced from MCL1 346 by S63845 and AZD5991 appears to undergo rapid degradation, as their levels in the treated 347 MARCH5 depleted or MCL1 overexpressing cells were not dramatically higher than in the 348 parental control cells ( Figure 7A -D). It is also possible that the high levels of NOXA and BIM in 349 the MARCH5 depleted cells and MCL1 overexpressing cells were effectively competing with 350 BAK for MCL1 binding, so that these cells are less dependent on MCL1 (and more dependent on 351 other anti-apoptotic BCL2 family proteins) to buffer BAK. However, arguing against this 13 mechanism, by coimmunoprecipitation we found that MCL1 was binding increased levels of 353 BAK, as well as NOXA and BIM, in the MARCH5 depleted cells and the MCL1 overexpressing 354 cells ( Figure 7E ). Alternatively, as MCL1 has a preference for binding BAK versus BAX (57), it 355 is possible that the increased levels of MCL1 are adequate to neutralize BAK even at drug 356 concentrations up to 10 µM. In support of this latter mechanism, we found that BAK was not 357 increased in the MARCH5 knockout cells ( Figure 7F ), which may allow the high levels of MCL1 358 to effectively buffer BAK despite treatment with S63845 or AZD5991. 359 In contrast to BAK, in the unactivated state BAX is localized primarily in the cytoplasm 360 and may be buffered mostly by BCLXL and BCL2. Significantly, BAX protein expression was 361 decreased in the MARCH5 knockout cells ( Figure 7F ). The decrease in BAX after MARCH5 loss 362 (as well as the decrease in PUMA) suggested that the MARCH5 knockout cells may have 363 decreased capacity to buffer BAX and be very sensitive to acute increases in free BAX, and 364 hence be more dependent on BCL2 or BCLXL. Therefore, we assessed responses to the 365 BCL2/BCLXL antagonist ABT-263 (navitoclax). Significantly, ABT-263 treatment caused a 366 marked apoptotic response specifically in the MARCH5 knockout cells ( Figure 7G ). As we 367 reported previously (22), ABT-263 could induce apoptosis in control parental cells in 368 combination with S63845, but the addition of S63845 only minimally enhanced apoptosis in the 369 ABT-263 treated MARCH5 knockout cells ( Figure 7H ). The BCL2 specific antagonist ABT-199 370 (venetoclax) was not effective, indicating that the efficacy of ABT-263 is due to BCLXL 371 inhibition ( Figure 7I ).
372
Of note, a previous study similarly found that MARCH5 knockdown could increase 373 MCL1 and sensitize to BCLXL inhibition, and suggested that increased NOXA was suppressing 374 the antiapoptotic activity of MCL1 (47). While this increased NOXA may be a factor, our data 375 indicate that the increased MCL1 in MARCH5 knockdown cells is sequestering substantial levels 376 of both BAK and BIM (see Figure 7E ). To explore other mechanisms, we examined the Avana 377 CRISPR screen dataset through the Broad DepMap site (https://depmap.org) to identify cell lines 378 that were dependent on MARCH5 and genes that have most similar patterns of dependency (58). 379 Interestingly, the gene that was most co-dependent with MARCH5 was MCL1 ( Figure 7J ,K). 380 Conversely, the gene most co-dependent with MCL1 was MARCH5. This strong co-dependency 381 was also observed in screens with another CRISPR library ( Figure S6A , B, C). Based on these 382 results and our data, we suggest that MARCH5, while acting as a ubiquitin ligase for NOXA- 14 liganded MCL1, may also have a distinct function in conjunction with MCL1 to suppress 384 mitochondrial membrane permeabilization by BAX. We reported previously that treatment with several kinase inhibitors could markedly increase 389 MCL1 degradation, and that this increase was not mediated by well-established MCL1 ubiquitin 390 ligases including βTRCP, FBW7, HUWE1 (22). In this study we initially found that erlotinib 391 treatment rapidly increased expression of NOXA, and that the increased MCL1 degradation was 392 NOXA-dependent. We subsequently found that the increase in NOXA was driven by ISR 393 activation, with subsequent increase in ATF4 protein and NOXA transcription. Previous studies 394 have shown that NOXA binding can increase the degradation of MCL1 (39), and have 395 implicated the ubiquitin ligases HUWE1 or PARKIN in this degradation (29, 31, 32, 46) . 396 However, we identified the mitochondria-associated ubiquitin ligase MARCH5 as the primary 397 mediator of this NOXA-dependent MCL1 degradation. Significantly, MARCH5 depletion both 398 abrogated the decrease in MCL1 in response to erlotinib and substantially increased basal MCL1 399 in multiple prostate, breast, and lung cancer cell lines, indicating that MARCH5 makes a major 400 contribution to regulating basal levels of MCL1. The physiological significance of MARCH5 as a 401 tumor suppressor gene through regulation of MCL1 is further supported by its genomic loss in a 402 subset of cancers. Importantly, MARCH5 depleted cells, which have increased levels of both 403 MCL1 and NOXA, have increased sensitivity to MCL1 antagonists (although at high 404 concentrations that may have off-target effects) and to the BH3 mimetic drug navitoclax (due to 405 targeting BCLXL), suggesting therapeutic approaches for MARCH5 deficient tumors. 406 The ISR with increased translation of ATF4 can be driven by multiple stimuli that 407 converge on phosphorylation of eIF2α, with subsequent increased translation of ATF4 and 408 increased expression of many genes that can contribute to resolving metabolic stress or driving 409 apoptosis. Importantly, the precise downstream consequences of ISR activation are context 410 dependent, but apoptosis is usually induced after prolonged stress and mediated by ATF4 411 induction of CHOP (59,60). However, ATF4 has been reported to directly upregulate the 412 PMAIP1 gene (encoding NOXA) (41,43), which would be consistent with the rapid time course 413 of NOXA induction that correlated with increased ATF4. The prominence of this ATF4 414 15 induction of NOXA in response to receptor tyrosine kinase inhibitors may reflect interactions 415 between multiple pathways downstream of these receptors, although we cannot rule out off target 416 effects on some ATP dependent processes. Indeed, treatment with erlotinib or lapatinib rapidly 417 increased basal oxygen consumption, indicating a shift towards oxidative phosphorylation to 418 increase ATP synthesis, and a metabolic stress that may contribute to ISR activation. 419 NOXA binding to MCL1 appears to stabilize a conformation that can drive its interaction 420 with ubiquitin ligases including HUWE1 and, as shown in this study, with MARCH5 (29, 30, 61) . 421 Indeed, the finding that MARCH5 depletion prevented the degradation of MCL1 in response to 422 NOXA induction indicates that MARCH5 is the major ubiquitin ligase mediating NOXA-423 induced MCL1 degradation. We further found that MARCH5 depletion increased MCL1 in 424 multiple cell lines, indicating that MARCH5 plays a substantial role in regulating MCL1 under 425 basal conditions, although this may still be NOXA-dependent and could reflect constitutive 426 levels of stress in tumor cells. This latter result is consistent with previous data from two groups 427 showing that that MARCH5 depletion can increase MCL1 (37,47). Interestingly, and consistent 428 with the latter study, we found that MARCH5 depletion was associated with an increase in 429 NOXA. This increase in NOXA was not due to increased p53-mediated transcription. Instead, it 430 reflects NOXA stabilization by MCL1 binding, as NOXA levels decreased rapidly when NOXA 431 was competed off with an MCL1 antagonist. However, we cannot rule out the possibility that 432 MARCH5 also indirectly regulates NOXA levels by coupling the degradation of MCL1 in 433 MCL1-NOXA complexes to the degradation of NOXA. 434 As MARCH5 is located on the mitochondrial outer membrane, we further asked whether 435 its degradation of MCL1 might be enhanced by drugs that perturb mitochondrial function. 436 Indeed, we found that all three agents examined (actinonin, gamitrinib-TPP, and CPI-613) 437 caused a MARCH5-dependent increase in MCL1 degradation. However, this did not appear to 438 reflect a direct effect on MARCH5. It was instead associated with a stress response, with 439 increased ATF4 and NOXA, similarly to the response to kinase inhibitors. These findings are 440 consistent with a previous study of gamitrinib-TPP that found this agent could activate a stress 441 response with an increase in NOXA and decrease in MCL1 (54). Further studies are needed to 442 determine whether MARCH5-mediated degradation of MCL1 can be enhanced by additional 443 agents that alter mitochondrial function through alternative mechanisms. 16 MCL1 is an inhibitor of apoptosis that acts by neutralizing BAK/BAX and by 445 sequestering activators of BAK/BAX such as BIM, and by also sequestering the less potent 446 activators NOXA and PUMA. Therefore, we anticipated that cells expressing high levels of 447 MCL1 due to MARCH5 depletion or overexpression of ectopic MCL1 would have increased 448 dependence on MCL1 to neutralize BAK/BAX and sequester BIM, NOXA, and PUMA. Indeed, 449 we confirmed that MCL1 was binding increased levels of these proteins in MARCH5 knockout 450 and MCL1 overexpressing cells, and that MCL1 antagonists could induce apoptosis in the 451 MARCH5 knockout and MCL1 overexpressing cells, but not the control cells. However, while 452 the apparent release of BIM and NOXA from MCL1 and their subsequent degradation were 453 observed at relatively low concentrations of S63845 or AZD5991, the induction of apoptosis 454 required ~20 µM of these drugs. This requirement for higher drug levels may reflect the very 455 high levels of MCL1 and its subsequent persistent engagement of BAK, despite treatment with 456 MCL1 antagonists. 457 The MARCH5 knockout cells also underwent apoptosis in response to BCLXL 458 antagonism with ABT-263, while apoptosis in the parental cells required antagonism of both 459 BCLXL and MCL1. A previous study similarly found that MARCH5 depletion could sensitize to 460 ABT-263, and suggested it may be due to high levels of NOXA that are antagonizing the 461 antiapoptotic functions of MCL1 (47). However, we found that MCL1 in MARCH5 knockout 462 cells was binding increased BAK and BIM, as well NOXA. Alternatively, as suggested by our 463 data, there may be a codependency between MARCH5 and MCL1 for buffering of BAX, so that 464 BCLXL in the MARCH5 knockout cells becomes critical to suppress the activity of BAX. 465 While more studies are clearly needed to further define how MARCH5 loss (or MCL1 466 amplification) alters responsiveness to BH3 mimetics, this study indicates that MARCH5 loss, 467 which appears to be relatively common in PCa, confers vulnerabilities to BH3 mimetic drugs. 468 However, challenges to exploiting these vulnerabilities include thrombocytopenia caused by 469 BCLXL inhibition, and the possible requirement for high concentrations of MCL1 antagonists, 470 whose toxicity profile remains to be established. Importantly, the available MCL1 antagonists 471 are all noncovalent and stabilize MCL1, which may limit their ability to abrogate MCL1 472 interaction with BAK. Therefore, it is possible that antagonists that drive MCL1 degradation, 473 possibly by mimicking the NOXA BH3 domain, might be more potent and effective. Finally, approaches that selectively cause robust ISR activation in tumor cells, with increased NOXA and 475 MCL1 degradation, may create an exploitable therapeutic window for BCLXL antagonists. (CSS) medium for 1 day. These cells were treated with erlotinib for 3 hours or EGF for 30 min 570 and were lysed in RIPA buffer supplemented with protease and phosphatase inhibitor cocktails. 571 The cell lysates were immediately boiled for 5 min in laemmli sample buffer with 2-572 mercaptoethanol and were applied to SuperSep Phos-tag gel (#198-17981, FUJIFILM WAKO 573 Chemicals), followed by immunoblotting for indicated proteins. Fig. S1 (Supplementary Fig. 1 ). EGFR inhibition increases proteasome-dependent MCL1 degradation. (A) LNCaP cells were pretreated with MG115 (10 μM) and MG132 (10 μM) for 30 min, followed by treatment with erlotinib for 4 hours. (B) LNCaP cells were treated with DMSO or erlotinib for 2 hours, followed by MCL1 mRNA measurement by qRT-PCR. 18s rRNA was used as an internal control. (n.s., not significant). Fig. S2 (Supplementary Fig. 3 Fig. S3 (Supplementary Fig. 3 Fig. S4 (Supplementary Fig. 5 Fig. S5 (Supplementary Fig. 6) . MARCH5 deletion is observed in subsets of PCa patients. Fig. S6 (Supplementary Fig. 7) . MARCH5 shows codependency with MCL1 in DepMap
CRISPR-CAS9 essentiality screens in cancer cells. (A) Correlation between MCL1 and
MARCH5 dependency scores in cancer cells from CRISPR-CAS9 screens using GeCKO libraries.
(B and C) Top 5 genes correlated with MCL1 dependency score (B) or genes correlated with MARCH5 dependency score (C) in cancer cells from CRISPR-CAS9 screens using GeCKO libraries.
Correlation with MCL1 dependency score Correlation with MARCH5 dependency score r = 0.614
GeCKO CRISPR library
